This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Serum Syndecan-1 Reflects Organ Dysfunction in Critically Ill Patients
Akio Suzuki
Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan.
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Syndecan-1 (SDC-1) is found in the endothelial glycocalyx and shed into the blood during systemic inflammatory conditions. We examined organ dysfunction associated with changing serum SDC-1 levels in critically ill patients. A single-center, retrospective, observational study was conducted at Gifu University Hospital. Patients admitted to the intensive care unit from March 2019 to February 2020 were enrolled. To evaluate the effect of SDC-1 on laboratory parameters measured the day after SDC-1 measurement with consideration for repeated measures, linear mixed effects models were constructed with each parameter as an outcome variable. A total of 94 patients were enrolled, and 831 samples were obtained. Analysis using mixed effects models for repeated measures with adjustment for age and sex showed that serum SDC-1 levels measured the day before significantly affected several outcomes, including aspartate aminotransferase (AST), alanine transaminase (ALT), creatinine (CRE), blood urea nitrogen (BUN), antithrombin III, fibrin degradation products, and D-dimer. Moreover, serum SDC-1 levels from the day before significantly modified the effect between time and several outcomes, including AST, ALT, CRE, and BUN. Serum SDC-1 may be a useful biomarker for daily monitoring of critically ill patients with kidney, liver and coagulation system injuries.
Keywords
Syndecan-1 (SDC-1), endothelial glycocalyx, creatinine, blood urea nitrogen (BUN), alanine transaminase
Figure 1
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Dec, 2020
No community comments so far
Review #12 received
Received 23 Dec, 2020
Review #16 received
Received 23 Dec, 2020
Review #15 received
Received 23 Dec, 2020
Review #14 received
Received 23 Dec, 2020
Review #13 received
Received 23 Dec, 2020
Review #1 received
Received 23 Dec, 2020
Reviewer #14 agreed
On 20 Dec, 2020
Reviewer #18 agreed
On 20 Dec, 2020
Reviewer #17 agreed
On 20 Dec, 2020
Reviewer #16 agreed
On 20 Dec, 2020
Reviewer #15 agreed
On 20 Dec, 2020
Reviewer #2 agreed
On 20 Dec, 2020
Reviewer #3 agreed
On 20 Dec, 2020
Reviewer #1 agreed
On 20 Dec, 2020
Reviewers invited
Invitations sent on 16 Dec, 2020
Editor assigned
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
First submitted
On 13 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Critical Care & Emergency Medicine
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Serum Syndecan-1 Reflects Organ Dysfunction in Critically Ill Patients
Akio Suzuki
Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan.
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Dec, 2020
No community comments so far
Review #12 received
Received 23 Dec, 2020
Review #16 received
Received 23 Dec, 2020
Review #15 received
Received 23 Dec, 2020
Review #14 received
Received 23 Dec, 2020
Review #13 received
Received 23 Dec, 2020
Review #1 received
Received 23 Dec, 2020
Reviewer #14 agreed
On 20 Dec, 2020
Reviewer #18 agreed
On 20 Dec, 2020
Reviewer #17 agreed
On 20 Dec, 2020
Reviewer #16 agreed
On 20 Dec, 2020
Reviewer #15 agreed
On 20 Dec, 2020
Reviewer #2 agreed
On 20 Dec, 2020
Reviewer #3 agreed
On 20 Dec, 2020
Reviewer #1 agreed
On 20 Dec, 2020
Reviewers invited
Invitations sent on 16 Dec, 2020
Editor assigned
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
First submitted
On 13 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Critical Care & Emergency Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Syndecan-1 (SDC-1) is found in the endothelial glycocalyx and shed into the blood during systemic inflammatory conditions. We examined organ dysfunction associated with changing serum SDC-1 levels in critically ill patients. A single-center, retrospective, observational study was conducted at Gifu University Hospital. Patients admitted to the intensive care unit from March 2019 to February 2020 were enrolled. To evaluate the effect of SDC-1 on laboratory parameters measured the day after SDC-1 measurement with consideration for repeated measures, linear mixed effects models were constructed with each parameter as an outcome variable. A total of 94 patients were enrolled, and 831 samples were obtained. Analysis using mixed effects models for repeated measures with adjustment for age and sex showed that serum SDC-1 levels measured the day before significantly affected several outcomes, including aspartate aminotransferase (AST), alanine transaminase (ALT), creatinine (CRE), blood urea nitrogen (BUN), antithrombin III, fibrin degradation products, and D-dimer. Moreover, serum SDC-1 levels from the day before significantly modified the effect between time and several outcomes, including AST, ALT, CRE, and BUN. Serum SDC-1 may be a useful biomarker for daily monitoring of critically ill patients with kidney, liver and coagulation system injuries.
Figure 1